A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron ( <scp>PF</scp> ‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron ( PF ‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus

Published:2022-12-19 Issue:3 Volume:25 Page:805-814
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Ono Ryosuke¹,Furihata Kenichi²,Ichikawa Yoshihiko¹,Nakazuru Yoshiomi¹,Bergman Arthur³,Gorman Donal N.⁴,Saxena Aditi R.³

Affiliation:

1. Pfizer Research and Development Japan Tokyo Japan

2. P‐One Clinic Tokyo Japan

3. Pfizer Worldwide Research and Development Cambridge Massachusetts USA

4. Pfizer Worldwide Research and Development Cambridge UK

Funder

Pfizer

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14928

Reference23 articles.

1. International Diabetes Federation.IDF Diabetes Atlas 10th Edition 2021.https://diabetesatlas.org/data/en/. Accessed July 19 2022.

2. Large-scale survey of rates of achieving targets for blood glucose, blood pressure, and lipids and prevalence of complications in type 2 diabetes (JDDM 40)

3. Three-Year Glycaemic Control and Management in Patients with Type 2 Diabetes Initiating Second-Line Treatment in Japan: A Prospective Observational Study, J-DISCOVER

4. Japanese Clinical Practice Guideline for Diabetes 2019

5. Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in small-molecule insulin secretagogues for diabetes treatment;Biomedicine & Pharmacotherapy;2024-09

2. Binding sites and design strategies for small molecule GLP-1R agonists;European Journal of Medicinal Chemistry;2024-09

3. [P³]PP, a stable, long‐acting pancreatic polypeptide analogue, evokes weight lowering and pancreatic beta‐cell‐protective effects in obesity‐associated diabetes;Diabetes, Obesity and Metabolism;2024-08-27

4. Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies;Diabetes, Obesity and Metabolism;2024-05-16

5. SpaceGrow: efficient shape-based virtual screening of billion-sized combinatorial fragment spaces;Journal of Computer-Aided Molecular Design;2024-03-17